Biotechnology Innovation Organization

MBX Biosciences Appoints Steven Ryder, M.D., to Board of Directors

Retrieved on: 
Monday, February 5, 2024
Pfizer, Growth, PEP, Therapy, Patient, BIO, Alexion Pharmaceuticals, Head, Food, Reata Pharmaceuticals, Society, Health, Regulation, Science, Hypoparathyroidism, Biotechnology Innovation Organization, Pharmacy, Pharmaceutical industry

CARMEL, Ind., Feb. 05, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. , a clinical-stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of endocrine disorders, today announced the appointment of Steven Ryder, M.D., Chief Medical Officer of Rallybio, to its Board of Directors.

Key Points: 
  • CARMEL, Ind., Feb. 05, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. , a clinical-stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of endocrine disorders, today announced the appointment of Steven Ryder, M.D., Chief Medical Officer of Rallybio, to its Board of Directors.
  • Dr. Ryder is an accomplished biopharmaceutical executive with over 35 years of global drug development experience and industry leadership.
  • “I am delighted to welcome Steve to our Board of Directors, and we look forward to his leadership as we progress our pipeline of novel therapies for people with rare endocrine disorders,” said Kent Hawryluk, President and Chief Executive Officer of MBX Biosciences.
  • “I am honored to join the MBX Board during this exciting period of growth for the Company,” said Dr. Ryder.

Ted Love, MD, Joins Gilead Sciences’ Board of Directors

Retrieved on: 
Thursday, February 1, 2024
Biotechnology, Hospitals, Pharmaceutical, Health, Cardiology, Massachusetts General Hospital, Senior, Hospital, Spirit, Distinguished Service Award, MD, Research, Sickle cell disease, Science, Yale school, Patient, Genentech, Therapy, Gilead Sciences, Development, Biotechnology Innovation Organization, Onyx Pharmaceuticals, Internal medicine

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Ted Love, MD, has been appointed to the company’s Board of Directors.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Ted Love, MD, has been appointed to the company’s Board of Directors.
  • Dr. Love is currently chair of the Board of Directors of the Biotechnology Innovation Organization and serves on the Boards of Directors of Royalty Pharma and Structure Therapeutics.
  • “We are delighted to welcome Ted Love to the Gilead Board of Directors,” said Daniel O’Day, Chairman and Chief Executive Officer of Gilead Sciences.
  • Ted will be a valuable addition to the Gilead Board as we continue to expand our impact on patients and communities worldwide.”

Alnylam CEO Yvonne Greenstreet Named 2024 Woman of the Year by Healthcare Businesswomen’s Association

Retrieved on: 
Tuesday, January 9, 2024
Biotechnology, Pharmaceutical, Health, BIO, Patient, GSK plc, Mentorship, Bloomberg, Medication, Health care, Health equity, Alnylam Pharmaceuticals, Harvard Medical School, University of Leeds, GSK, Capital Group Companies, Science, Science (journal), Workplace, RNA interference, Environment, MBA, Conference, HBA, Biotechnology Innovation Organization, HSGB, University, Therapy, Research, Parent, Growth, Management

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, said today that Chief Executive Officer Yvonne Greenstreet has been selected as the 2024 Woman of the Year by the Healthcare Businesswomen’s Association (HBA).

Key Points: 
  • Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, said today that Chief Executive Officer Yvonne Greenstreet has been selected as the 2024 Woman of the Year by the Healthcare Businesswomen’s Association (HBA).
  • Yvonne will be recognized at HBA’s 34th annual Woman of the Year event on May 10 in New York City.
  • The HBA Woman of the Year award honors an executive leader who has made extraordinary contributions to healthcare and the advancement of women in the workplace.
  • “Yvonne demonstrates leadership from the front,” said David Pyott, retired chairman and CEO of Allergan and a member of Alnylam’s board of directors.

TORL BioTherapeutics Announces Appointment of Mark J. Alles as Chairman and Chief Executive Officer; Highlights Significant Progress of its Oncology Clinical Programs

Retrieved on: 
Tuesday, January 9, 2024
Entrepreneurship, Bristol Myers Squibb, LOS, BIO, Patient, Pharmacy, EFPIA, ADC, CFO, Hematology, Executive, BioMarin Pharmaceutical, Spacecraft, Biotechnology Innovation Organization, Acquisition, Drug development, UCLA, FDA, Janssen Pharmaceuticals, Marine Corps Expeditionary Medal, Therapy, United States of Europe, Colorectal cancer, Bayer, Growth, Pharmaceutical industry

Mark Alles, Executive Chairman of TORL BioTherapeutics, LLC (TORL) and former Chairman and CEO of Celgene Corporation has been appointed TORL's Chairman and CEO.

Key Points: 
  • Mark Alles, Executive Chairman of TORL BioTherapeutics, LLC (TORL) and former Chairman and CEO of Celgene Corporation has been appointed TORL's Chairman and CEO.
  • Today, the company announced the appointment of Mark J.  Alles, TORL's Executive Chairman, as the company's new Chairman and CEO.
  • Prior to joining Celgene in 2004, Mr. Alles was Vice President of the U.S. Oncology business unit at Aventis Pharmaceuticals.
  • He began his industry career at Bayer and Centocor after serving as a Captain in the United States Marine Corps.

Illinois Biotechnology Innovation Organization Elects New Board Chair and Adds New Board Members

Retrieved on: 
Monday, January 8, 2024
Biotechnology Innovation Organization, Research, Chair, Chairperson, Pharming, Congress, Growth, Patient, Senior, Management

CHICAGO, Jan. 8, 2024 /PRNewswire-PRWeb/ -- Today, the Illinois Biotechnology Innovation Organization, iBIO, the trade association representing the 91,000 jobs in Illinois' life sciences sector, announced a new Chair and added three new members to its Board of Directors. Ken Johnson, Pharm.D., senior vice president for global development and medical affairs at Xeris Biopharma, transitioned to Chair of the board. Heidi Gilmore from TerSera, Joe Hrdlicka from Genentech, and Kevin Johnson from Amgen have joined the Board of Directors.

Key Points: 
  • Illinois Biotechnology Innovation Organization (iBIO) announced a new Chair and added three new members to its Board of Directors.
  • CHICAGO, Jan. 8, 2024 /PRNewswire-PRWeb/ -- Today, the Illinois Biotechnology Innovation Organization, iBIO, the trade association representing the 91,000 jobs in Illinois' life sciences sector, announced a new Chair and added three new members to its Board of Directors.
  • Ken Johnson, Pharm.D., senior vice president for global development and medical affairs at Xeris Biopharma, transitioned to Chair of the board.
  • "I am excited to work with the board and our members to advance policies that drive innovation, foster collaboration, and promote the growth of Illinois' biosciences industry."

Ginkgo Bioworks Announces Inaugural Members of New Biopharma Advisory Board

Retrieved on: 
Monday, January 8, 2024
Commercial, Boehringer Ingelheim, DNA, Cancer, Investment, Novartis, SVP, Fermentation, Beam, Atlas, Kite Pharma, RNA interference, Sensible, Drug discovery, AbbVie, Invention, Biotechnology Innovation Organization, Eli Lilly, MBA, HIV, Merck, Therapy, Creativity, Epidemiology, RNA, GSK plc, DARPA, Process, WARF, Johnson & Johnson, Movement, Ginkgo Bioworks, Novo Nordisk, AI, Atlas Venture, AAV, Patient, Medicine, Synthetic biology, Senior, M28, Acquisition, BIO, MD, Doctor of Philosophy, Eli Lilly and Company, Hematology, Growth, Avantor, Infection, Pharmaceutical industry

BOSTON, Jan. 8, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the formation of its new Biopharma Advisory Board.

Key Points: 
  • BOSTON, Jan. 8, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the formation of its new Biopharma Advisory Board.
  • "The discovery and development of new medicines is critically important and incredibly challenging," said Jason Kelly, co-founder and CEO of Ginkgo Bioworks.
  • "I'm excited to welcome this incredible deep bench of wisdom and creativity to the Ginkgo family," said Jennifer Wipf, SVP & Head of Commercial at Ginkgo Bioworks.
  • Now more than ever, the speed of drug discovery and development is important," said Norbert Bischofberger, Ginkgo Biopharma Advisory Board member.

Evolus Announces the Appointment of Nareg Sagherian to Vice President, Head of Global Investor Relations and Corporate Communications

Retrieved on: 
Thursday, January 4, 2024
Cosmetics, Retail, Pharmaceutical, Health, Small Business Administration, University School, Public policy, Corporate Affairs, Medicine, Biotechnology Innovation Organization, Booz Allen Hamilton, Corporate communication, Georgetown University, Narek, Graduate diploma, FTI Consulting, Intercept Pharmaceuticals, Treasury, Small business, University, Public sector, Executive director, Corporate finance, Carey Business School, Management

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that Nareg Sagherian has joined the Company as Vice President, Head of Global Investor Relations and Corporate Communications.

Key Points: 
  • Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that Nareg Sagherian has joined the Company as Vice President, Head of Global Investor Relations and Corporate Communications.
  • In this role, Nareg will be responsible for interacting with current and prospective investors and managing a strategic investor relations and corporate communications program.
  • “Nareg’s unique experience will enable him to drive a successful investor relations strategy that communicates Evolus’ strategic goals to our stakeholders.”
    Prior to joining Evolus, Nareg was the Executive Director, Head of Global Investor Relations, Corporate Affairs for Intercept Pharmaceuticals.
  • Nareg brings extensive experience in capital markets, investor relations, corporate communications, and public policy to Evolus from firms including FTI Consulting, Biotechnology Innovation Organization and Booz Allen Hamilton.

Intellia Therapeutics Highlights its Three-Year Strategic Priorities and Anticipated 2024 Key Milestones

Retrieved on: 
Thursday, January 4, 2024
Liver, Conference, Science, Gene editing, Biotechnology Innovation Organization, Amyloidosis, BIO, CRISPR, Phase 1, Tissue, DNA, Cardiomyopathy, Therapy, ATTR, Intellia Therapeutics, NTLA, Clinical trial, Polyneuropathy, NK, AATD, Lung, Hereditary angioedema, Webcast, Patient, Medicine, HAE, BLA, Pharmaceutical industry

Organizational Streamlining: Following an internal strategic review, Intellia will be streamlining company-wide operations to further focus resources on key strategic priorities and programs.

Key Points: 
  • Organizational Streamlining: Following an internal strategic review, Intellia will be streamlining company-wide operations to further focus resources on key strategic priorities and programs.
  • Cash Runway: Intellia ended the fourth quarter of 2023 with approximately $1.0 billion in cash, cash equivalents and marketable securities.
  • Prepare for the Phase 3 study of NTLA-2001 for the treatment of ATTR amyloidosis with polyneuropathy (ATTRv-PN) in 2024.
  • A live webcast will be available through the Events and Presentations page of the Investors & Media section on Intellia’s website, www.intelliatx.com .

Amicus Therapeutics Congratulates Executive Chairman John F. Crowley on Appointment as Next President and CEO of BIO

Retrieved on: 
Tuesday, December 5, 2023
Amicus Therapeutics, Policy, Partnership, Biotechnology Innovation Organization, Biotechnology, BIO, Hope, Therapy, Patient, Organization, Management

PRINCETON, N.J., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Executive Chairman of Amicus Therapeutics, will step down from the Amicus Board of Directors and assume the role of President and Chief Executive Officer of BIO, the Biotechnology Innovation Organization, effective March 4, 2024. Michael Raab, Lead Independent Director, will become the Chairman of the Amicus Board of Directors. BIO is based in Washington, DC and is the world’s largest biotechnology policy and advocacy association, representing the entire biotechnology industry, with over 1,200 member organizations worldwide.

Key Points: 
  • PRINCETON, N.J., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Executive Chairman of Amicus Therapeutics, will step down from the Amicus Board of Directors and assume the role of President and Chief Executive Officer of BIO, the Biotechnology Innovation Organization, effective March 4, 2024.
  • Michael Raab, Lead Independent Director, will become the Chairman of the Amicus Board of Directors.
  • BIO is based in Washington, DC and is the world’s largest biotechnology policy and advocacy association, representing the entire biotechnology industry, with over 1,200 member organizations worldwide.
  • Mr. Crowley joined Amicus in 2005 and served as Chairman and Chief Executive Officer until 2022, when he transitioned to his current role as Executive Chairman.

BioMarin Announces Governance Enhancements and Value Creation Initiatives

Retrieved on: 
Wednesday, December 20, 2023
Adverum Biotechnologies, University, Ambit Biosciences, Daiichi Sankyo, Hill-Rom, Indiana University, Harvard Law School, Baxter, Acceleration, Strategy, Palmer, Pfizer, Biotechnology Innovation Organization, Invacare, Eli Lilly, Hospira, Pediatrics, Chairperson, The Nature Conservancy, Genzyme, American Cancer Society, Therapy, Goldman Sachs, M.B.A, BMRN, ImmunoGen, DSM-IV codes, Shire (pharmaceutical company), IPO, Patient, Proteostasis, BioMarin Pharmaceutical, Corporate development, Dentsply Sirona, Senior, Syneos Health, Iovance Biotherapeutics, Sclerosis, Acquisition, SAN, CIO, Eli Lilly and Company, Interim, Bristol Myers Squibb, Information technology, Management

SAN RAFAEL, Calif., Dec. 20, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today announced several initiatives to enhance corporate governance and long-term shareholder value creation.

Key Points: 
  • SAN RAFAEL, Calif., Dec. 20, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today announced several initiatives to enhance corporate governance and long-term shareholder value creation.
  • "Today's announcements will strengthen our ability to drive better outcomes for patients with genetic diseases and deliver value to all stakeholders.
  • BioMarin plays a pivotal role in the treatment of genetic diseases thanks to its globally leading rare-disease portfolio.
  • We believe the changes announced today put BioMarin in the best position to realize its full potential, and we support Alexander Hardy as the right leader for this chapter of BioMarin's value creation story.